GSK’s (GSK) Buy Rating Reiterated at Jefferies Financial Group

GSK (LON:GSK)‘s stock had its “buy” rating restated by analysts at Jefferies Financial Group in a report released on Wednesday,Digital Look reports. They presently have a GBX 2,500 price objective on the stock. Jefferies Financial Group’s target price suggests a potential upside of 22.55% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Citigroup decreased their price target on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 1,950 price target on shares of GSK in a research report on Monday. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of GBX 2,041.43.

GSK Stock Performance

LON GSK opened at GBX 2,040 on Wednesday. The firm has a market capitalization of £81.71 billion, a P/E ratio of 14.36, a PEG ratio of 1.24 and a beta of 0.30. GSK has a fifty-two week low of GBX 1,288.61 and a fifty-two week high of GBX 2,282. The stock has a 50-day simple moving average of GBX 1,935.75 and a two-hundred day simple moving average of GBX 1,990.76. The company has a debt-to-equity ratio of 106.74, a quick ratio of 0.73 and a current ratio of 0.79.

GSK (LON:GSK) last posted its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. On average, equities analysts forecast that GSK will post 175.980975 earnings per share for the current year.

Insider Transactions at GSK

In other news, insider Jonathan Symonds purchased 1,550 shares of the stock in a transaction on Friday, June 19th. The stock was bought at an average price of GBX 1,935 per share, for a total transaction of £29,992.50. Also, insider Vishal Sikka acquired 1,266 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were purchased at an average cost of GBX 5,069 per share, with a total value of £64,173.54. Over the last ninety days, insiders purchased 3,625 shares of company stock valued at $13,495,004. 0.20% of the stock is currently owned by corporate insiders.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK raised its margin outlook and announced plans to generate approximately £1.9 billion (about $2.5 billion) in annual savings. The savings are expected to come from mature products, procurement and supply-chain efficiencies, helping fund research and development and accelerate new medicines. GSK Plans Annual Savings of £1.9 Billion to Enable R&D Spend
• Positive Sentiment: Partner Hansoh reported a successful late-stage trial for a bone-cancer therapy licensed by GSK. The result strengthens GSK’s oncology pipeline, although regulatory approval and the eventual commercial contribution remain uncertain. GSK partner Hansoh posts late-stage trial win for bone cancer therapy
• Positive Sentiment: GSK reported quarterly EPS of GBX 54.10, with a 35.78% return on equity and a 17.78% net margin, providing evidence of continued profitability as management reshapes the business.
• Neutral Sentiment: GSK plans to close its historic Stevenage research site and shift research activity to Cambridge. Management says the consolidation should improve drug-development speed, but the transition could create execution and employee-relations risks. GSK to shut historic Stevenage site and switch research centre to Cambridge
• Negative Sentiment: The restructuring involves job reductions and reflects GSK’s preparation for a patent cliff, raising concerns about future revenue pressure as key products lose exclusivity. GSK prepares for patent cliff with $2.5B cost-cutting plan
• Negative Sentiment: Deutsche Bank reaffirmed its “Hold” rating and set a GBX 1,950 price target, below the stock’s recent trading level, signaling limited near-term upside in the bank’s view. Deutsche Bank Reaffirms Hold Rating for GSK

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.